IMMUNE / INFLAMMATION / PEPTIDE CARD

Thymosin Alpha-1

A synthetic version of a thymic peptide investigated as an immune modulator and used clinically in some countries outside the United States.

PEPTIDE CARDThymosin Alpha-1

Reviewed
August 8, 2026

Human evidence

3/5 · Substantial but mixed research

U.S. FDANot FDA approved

2026 WADANot specifically named

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

Thymosin Alpha-1 evidence summary.

Thymosin alpha-1 has more human research than many wellness-market peptides, yet the evidence remains indication-specific and does not amount to U.S. approval or a general immune-boosting claim.

Entity type
Synthetic peptideSource snapshot
August 8, 2026Record status
Sources attached

Do not overread this record

A large evidence base can still be inconsistent; trial quality, population, co-therapies, and endpoint selection determine what can be concluded.

01 / CLASSIFICATION

What is Thymosin Alpha-1?

Entity typeSynthetic peptide

Research categoryImmune / Inflammation

Known namesThymosin Alpha-1, Thymalfasin

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Thymosin-related peptides Class: Innate-immunity and inflammation peptides Goal: Immune & Inflammation

02 / EVIDENCE

Thymosin Alpha-1 human and preclinical evidence.

HUMAN

3/5 · Substantial but mixed research

Human trials and meta-analyses exist across immune and infectious-disease settings, but results and study quality vary by indication.

PRECLINICAL

4/5 · Established immune biology

Immunologic mechanisms are widely studied; mechanism alone does not settle clinical benefit for a specific disease.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Thymosin Alpha-1 FDA and sport status.

U.S. FDANo FDA-approved thymosin alpha-1 drug product identified in the August 2026 source snapshot; products are used in some countries outside the United States.

2026 WADANot specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Thymosin Alpha-1 being studied for?

01Sepsis

02Immune modulation

03Infectious disease

04Oncology adjunct research

05 / COMPARISONS

Compare Thymosin Alpha-1.

Thymosin Alpha-1 vs Thymosin Beta-4Two distinct thymosin peptides with different biology, research programs, and sport status.Thymosin Alpha-1 vs LL-37An immune-modulating therapeutic candidate compared with an endogenous antimicrobial peptide.

06 / LATEST & DEFINING SOURCES

Thymosin Alpha-1 primary and official sources.

Human trial / 2025Thymosin alpha-1 for sepsis: multicenter randomized phase 3 trial

PubMed

Review / 2025Thymosin alpha-1 in sepsis: systematic review and meta-analysis

PubMed

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Thymosin Alpha-1.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Thymosin Alpha-1?

Thymosin alpha-1 has more human research than many wellness-market peptides, yet the evidence remains indication-specific and does not amount to U.S. approval or a general immune-boosting claim.

ResearchWhat is Thymosin Alpha-1 being studied for?

Current source-backed research areas include Sepsis, Immune modulation, Infectious disease, Oncology adjunct research. These areas describe investigation, not established personal benefit.

FDA statusIs Thymosin Alpha-1 FDA approved?

Current U.S. status for Thymosin Alpha-1: No FDA-approved thymosin alpha-1 drug product identified in the August 2026 source snapshot; products are used in some countries outside the United States.

Sport statusIs Thymosin Alpha-1 prohibited in sport?

Current sport-status snapshot for Thymosin Alpha-1: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Evidence limitsWhat are the main evidence limits for Thymosin Alpha-1?

A large evidence base can still be inconsistent; trial quality, population, co-therapies, and endpoint selection determine what can be concluded.